Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study
Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study have?
Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study has 38 citations in the OpenAlex counts ScholarIQ stores.
When was Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study published?
Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study has 2019 year in the ScholarIQ index.
What is the open-access status of Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study?
Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study has hybrid oa status in the ScholarIQ index.
What is the DOI of Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study?
The DOI for Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study is on the source record.
What is the PMID of Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study?
The PMID for Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study is on the source record.
What is the OpenAlex record for Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study?
The OpenAlex for Targeted Agents or Immuno-Oncology Therapies as First-Line Therapy for BRAF-Mutated Metastatic Melanoma: A Real-World Study is on the source record.